Amring Pharmaceuticals gains rights to six ANDAs

Privately-held US generic drugmaker Amring Pharmaceuticals says it acquired six Abbreviated New Drug Applications (ANDAs), which include ANDAs include niche otic and ophthalmic pharmaceuticals that will bring value to our customers and patients.

The products come from Luitpold Pharmaceuticals, a USA-based subsidiary of Japan’s Daiichi Sankyo (TYO: 4568), and AlphaForce, a joint venture between Luitpold Pharmaceuticals and Alphagen Laboratories. No financial terms of the deal were disclosed.

Daniel Carbery, president of Amring, stated: “We are pleased with our progress during the past year and look forward to realizing the benefits of our business development activities in 2017.”